跳至主要内容
临床试验/NCT05992701
NCT05992701已完成不适用

Effectiveness and Safety of Directional Deep Brain Stimulation for Parkinson's Disease

Beijing Pins Medical Co., Ltd16 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2021年7月28日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
26
试验地点
16
主要终点
Therapeutic Window

研究概览

简要总结

The purpose of this study is to demonstrate the safety and effectiveness of the PINS Deep Brain Stimulation (DBS) system, including the G107R/G107 IPG, L305/L306 directional leads, E204 extensions and related system components.

详细描述

This is a prospective, open label, non-randomized study. The study will evaluate the clinical outcome and possible adverse effects of the directional DBS treatment. The following data will be collected: therapeutic window, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating (MDS-UPDRS) Part III scores, Parkinson's Disease Questionnaire (PDQ-39) summary scores, total electrical energy delivered, the dosage of anti-parkinsonian medications, on time(h/d) without troublesome dyskinesia, and adverse events.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age at the time of enrollment: 18 ~ 75;
  • •Idiopathic Parkinson's disease;
  • •Patient whose symptoms are not adequately controlled by best medical therapy;
  • •Hoehn and Yahr stage≥2.5;
  • •Patient whose symptoms are improved by at least 30% with levodopa challenge test;
  • •Must be an appropriate candidate for the surgical procedures required for bilateral DBS;
  • •Is willing and able to comply with all visits and study related procedures;
  • •Patient understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed.

排除标准

  • •Had received lesioning surgical treatment;
  • •A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception;
  • •Any current drug or alcohol abuse;
  • •Cognitive impairment (MMSE≦17 for primary school education or MMSE≦24 for middle school education and above);
  • •Any significant psychiatric problems, including unrelated clinically significant depression;
  • •Any history of craniocerebral injury, tumor, or severe cerebrovascular disease;
  • •Severe brain atrophy (confirmed by CT or MRI);
  • •A condition requiring or likely to require the use of diathermy;
  • •Abnormal blood routine or biochemical test, coagulation dysfunction, serious abnormal liver or kidney function;
  • •Uncontrolled high blood pressure, serious heart disease or serious medical or respiratory diseases;
  • •Long-term of immunosuppressive or hormone therapy;
  • •Other diseases requiring the stimulators;
  • •A condition requiring or likely to require the use of MRI;
  • •Participated in any other clinical trials within the preceding 3 months;
  • •Unwilling or unable to cooperate with the implantation of DBS system;
  • •Unwilling or unable to cooperate with postoperative follow-up;
  • •Not considered to be applicable by the investigator.

研究组 & 干预措施

Directional deep brain stimulation

Experimental

干预措施: Directional deep brain stimualtion (Device)

结局指标

主要结局

Therapeutic Window

时间窗: 1 month post the device implanted

Therapeutic window is the range of stimulation amplitude that produces symptom relief without causing side effects.

次要结局

  • Motor Function(3 months post device-activation)
  • Total Electrical Energy Delivered(TEED)(3 months post device-activation)
  • The dosage of anti-parkinsonian medications(3 months post device-activation)
  • On time(h/d) without troublesome dyskinesia(3 months post device-activation)
  • Adverse events(3 months post device-activation)
  • The dosage of anti-parkinsonian medications(3 months post device-activation)
  • Motor Function(3 months post device-activation)
  • Total Electrical Energy Delivered(TEED)(3 months post device-activation)
  • Adverse events(3 months post device-activation)
  • Change in PDQ-39 score(3 months post device-activation)
  • On time(h/d) without troublesome dyskinesia(3 months post device-activation)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验